Empreses emergents
2016
METABOSTEM SLEl segell distintiu de metabostemness proporciona un marc únic per descobrir i desenvolupar fàrmacs innovadors destinats a reescriure o desinstal·lar el sistema operatiu metabòlic de les CSC. L'empresa va cessar l'activitat.
Adreça
Carrer de Calàbria 241, 08029 Barcelona, Espanya
Propietat CERCA
Contacte del Centre CERCA
AV
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
METABOSTEM is a Barcelona-based Biopharmaceutical Company passionately committed to transforming the lives of cancer patients by entering a new dimension of precision medicine. The pioneering science behind METABOSTEM has the goal of developing breakthrough oncology drugs directed to the unique metabolic features of cancer stem cells (CSCs), the most dangerous & deadliest type of cancer cell. The Company is a spinout of the Catalan Institute of Oncology.
Descripció del producte
MS-001: A FIRST-IN-CLASS, DUAL-ACTION METABOLO-EPIGENETIC DRUG
The Company is currently in the late preclinical testing stages and early formulation development of its most advanced chemical lead candidate, MS-001. MS-001 is a first-in-class, dual-action metabolo-epigenetic drug. Using METABOSTEM’s scientific knowledge of the metabostemness cancer hallmark, METABOSTEM identified MS-001 as a valuable drug candidate for eradicating CSCs. Research on MS-001 included a systematic analysis of the anti-CSC activity on in vitro and in vivo human-derived models of biologically aggressive, CSC-enriched types of human carcinomas.
The Company is currently in the late preclinical testing stages and early formulation development of its most advanced chemical lead candidate, MS-001. MS-001 is a first-in-class, dual-action metabolo-epigenetic drug. Using METABOSTEM’s scientific knowledge of the metabostemness cancer hallmark, METABOSTEM identified MS-001 as a valuable drug candidate for eradicating CSCs. Research on MS-001 included a systematic analysis of the anti-CSC activity on in vitro and in vivo human-derived models of biologically aggressive, CSC-enriched types of human carcinomas.
Empresa tancada o sortida